| Revision as of 12:27, 10 December 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmac...← Previous edit | Latest revision as of 19:39, 4 February 2024 edit undoVastV0idInSpace0 (talk | contribs)Extended confirmed users2,408 edits Fixed spacing between stub template and category templatesTag: 2017 wikitext editor | ||
| (22 intermediate revisions by 18 users not shown) | |||
| Line 1: | Line 1: | ||
| {{Short description|Chemical compound}} | |||
| {{cs1 config|name-list-style=vanc}} | |||
| {{Drugbox | {{Drugbox | ||
| | Verifiedfields = changed | |||
| ⚫ | | verifiedrevid = |
||
| | Watchedfields = changed | |||
| ⚫ | | verifiedrevid = 477227464 | ||
| | IUPAC_name = 8a-phenyldecahydroquinoline | | IUPAC_name = 8a-phenyldecahydroquinoline | ||
| | image = Phenyldecahydroquinoline.svg | | image = Phenyldecahydroquinoline.svg | ||
| Line 15: | Line 19: | ||
| <!--Identifiers--> | <!--Identifiers--> | ||
| | CAS_number_Ref = {{cascite| |
| CAS_number_Ref = {{cascite|changed|??}} | ||
| | CAS_number = 131556-11-1 | | CAS_number = 131556-11-1 | ||
| | UNII_Ref = {{fdacite|correct|FDA}} | |||
| | UNII = 8GBT78N4EC | |||
| | PubChem = 131397 | | PubChem = 131397 | ||
| | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ||
| Line 23: | Line 29: | ||
| <!--Chemical data--> | <!--Chemical data--> | ||
| | C=15 | H=21 | N=1 | | C=15 | H=21 | N=1 | ||
| | smiles = C1(23CCCC2CCCN3)=CC=CC=C1 | |||
| | molecular_weight = 215.3339 g/mol | |||
| | smiles = c1ccccc1C32NCCCC2CCCC3 | |||
| | InChI = 1/C15H21N/c1-2-7-13(8-3-1)15-11-5-4-9-14(15)10-6-12-16-15/h1-3,7-8,14,16H,4-6,9-12H2 | |||
| | InChIKey = QEXADSRMRUUCQJ-UHFFFAOYAG | |||
| | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | ||
| | StdInChI = 1S/C15H21N/c1-2-7-13(8-3-1)15-11-5-4-9-14(15)10-6-12-16-15/h1-3,7-8,14,16H,4-6,9-12H2 | | StdInChI = 1S/C15H21N/c1-2-7-13(8-3-1)15-11-5-4-9-14(15)10-6-12-16-15/h1-3,7-8,14,16H,4-6,9-12H2 | ||
| Line 33: | Line 36: | ||
| }} | }} | ||
| '''8a-Phenyldecahydroquinoline''' ('''8A-PDHQ''') is a high affinity ]. It is a structural analog of ] with slightly lower binding affinity than the parent compound. ( |
'''8a-Phenyldecahydroquinoline''' ('''8A-PDHQ''') is a high affinity ] developed by a team at Parke Davis in the 1950s.<ref>US Patent 3035059</ref> It is a structural analog of ] with slightly lower binding affinity than the parent compound. (−)-8a-Phenyldecahydroquinoline has an in vivo potency comparable to that of (+)-].<ref>{{cite journal | vauthors = Chen C, Kozikowski AP, Wood PL, Reynolds IJ, Ball RG, Pang YP | title = Synthesis and biological activity of 8a-phenyldecahydroquinolines as probes of PCP's binding conformation. A new PCP-like compound with increased in vivo potency | journal = Journal of Medicinal Chemistry | volume = 35 | issue = 9 | pages = 1634–8 | date = May 1992 | pmid = 1315871 | doi = 10.1021/jm00087a020 }}</ref><ref>{{cite journal | vauthors = Elhallaoui M, Laguerre M, Carpy A, Ouazzani FC | title = Molecular modeling of noncompetitive antagonists of the NMDA receptor: proposal of a pharmacophore and a description of the interaction mode | journal = Journal of Molecular Modeling | volume = 8 | issue = 2 | pages = 65–72 | date = February 2002 | pmid = 12032600 | doi = 10.1007/s00894-001-0067-4 | s2cid = 34882820 }}</ref> | ||
| == References == | == References == | ||
| {{reflist}} | {{reflist}} | ||
| {{Hallucinogens}} | |||
| {{Ionotropic glutamate receptor modulators}} | |||
| ⚫ | {{DEFAULTSORT:Phenyldecahydroquinoline, 8a-}} | ||
| ] | |||
| {{Dissociative_hallucinogens}} | |||
| {{Glutamate_receptor_ligands}} | |||
| ⚫ | {{DEFAULTSORT:Phenyldecahydroquinoline, 8a-}} | ||
| ] | ] | ||
| ] | ] | ||
| ] | ] | ||
| ] | |||
Latest revision as of 19:39, 4 February 2024
Chemical compoundPharmaceutical compound
 | |
| Identifiers | |
|---|---|
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C15H21N |
| Molar mass | 215.340 g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (what is this?) (verify) | |
8a-Phenyldecahydroquinoline (8A-PDHQ) is a high affinity NMDA antagonist developed by a team at Parke Davis in the 1950s. It is a structural analog of phencyclidine with slightly lower binding affinity than the parent compound. (−)-8a-Phenyldecahydroquinoline has an in vivo potency comparable to that of (+)-MK-801.
References
- US Patent 3035059
- Chen C, Kozikowski AP, Wood PL, Reynolds IJ, Ball RG, Pang YP (May 1992). "Synthesis and biological activity of 8a-phenyldecahydroquinolines as probes of PCP's binding conformation. A new PCP-like compound with increased in vivo potency". Journal of Medicinal Chemistry. 35 (9): 1634–8. doi:10.1021/jm00087a020. PMID 1315871.
- Elhallaoui M, Laguerre M, Carpy A, Ouazzani FC (February 2002). "Molecular modeling of noncompetitive antagonists of the NMDA receptor: proposal of a pharmacophore and a description of the interaction mode". Journal of Molecular Modeling. 8 (2): 65–72. doi:10.1007/s00894-001-0067-4. PMID 12032600. S2CID 34882820.
| Ionotropic glutamate receptor modulators | |
|---|---|
| AMPARTooltip α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor |
|
| KARTooltip Kainate receptor |
|
| NMDARTooltip N-Methyl-D-aspartate receptor |
|
 | This hallucinogen-related article is a stub. You can help Misplaced Pages by expanding it. |